ERAS ERASCA INC

Erasca to Present at Upcoming Investor Conferences

Erasca to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings.

Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)

Location: InterContinental Hotel, Boston, MA

Format: Fireside Chat

Date and Time: Tuesday, November 12, 2:00 pm Eastern Time

Jefferies London Healthcare Conference (November 19 – 21, 2024)

Location: The Waldorf Hilton, London, UK

Format: Presentation

Date and Time: Wednesday, November 20, 12:30 pm Greenwich Mean Time

7th Annual Evercore HealthCONx Conference (December 3 – 5, 2024)

Location: Loews Coral Gables Hotel, Coral Gables, FL

Format: Fireside Chat

Date and Time: Wednesday, December 4, 11:15 am Eastern Time

A live audio webcast of the events will be available online at . An archived replay of the events will be available for 90 days following the webcast at .

About Erasca

At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:

Joyce Allaire

LifeSci Advisors, LLC

Source: Erasca, Inc.



EN
05/11/2024

Underlying

ERASERASCA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ERASCA INC

 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca Reports Third Quarter 2024 Business Updates and Financial Resul...

Erasca Reports Third Quarter 2024 Business Updates and Financial Results Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eras...

November 12, 2024 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca to Present at Upcoming Investor Conferences

Erasca to Present at Upcoming Investor Conferences SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings. Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)Location: InterContinental Hotel, Boston, MAFormat: Fireside Chat Date a...

November 5, 2024 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Fra...

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial SEACRAFT-2 has potential for approval based on alignment with US and European regulatory agencies on path for tissue-specific indication in melanoma; Stage 1 randomized data expected in 2025 Rapid progress across RAS targeting franchise; planned IND submissions remain on track Erasca to host investor event today at 8:30 AM Eastern Tim...

October 24, 2024 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib ...

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma where favorable survival was previously demonstrated in pooled analyses Erasca to host virtual R&D update for investors on Thursday, October 24, 2024, at 8:30 AM ET SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasc...

September 25, 2024 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca to Present at Upcoming Investor Conferences in September

Erasca to Present at Upcoming Investor Conferences in September SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in September 2024 and will also participate in one-on-one investor meetings. 22nd Annual Morgan Stanley Global Healthcare ConferenceLocation: New York Marriott Marquis, New York, NYFormat: Fireside...

August 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch